Germany news - the latest biotech news from Labiotech.eu

Home Germany Page 21

Latest Posts

max planck marburg synthetic biology

News and Trends 28 Nov 2016

SynBio reinvents Photosynthesis with artificial CO2-fixing Pathway

Removing CO2 from the atmosphere could help with climate change, and there’s now a new biological method in the making to achieve this. Researchers have developed a new turbo-charged version of a metabolic pathway for fixing CO2, which is 20% more efficient than in plants. As described in an article just published in Science, a […]

November 28, 2016 - 3 minutesmins - By Denise Neves Gameiro

Screenshot 2016 11 22 at 1.33.19 PM e1479818165882

News and Trends 25 Nov 2016

Structural Biology meets Drug Discovery in this Cool Company

After an amazing day in Paris for Labiotech Refresh, we head back to Germany to meet Proteros. The company is working non-stop to provide drug candidates against some of the hottest targets in biotech. City: Munich, Germany Founded: 1999 Employees: 80+ Financial data: The company just announced a €157M ($167M) deal with MSD Mission: Proteros’ expertise in structural biology […]

November 25, 2016 - 1 minutemin - By Clara Rodríguez Fernández

Screenshot 2016 11 18 at 11.23.36 AM e1479464682197

News and Trends 18 Nov 2016

These Spider Silk Sneakers from Adidas Are Biodegradable

Adidas just unveiled a biodegradable sneaker prototype made with a spider silk biomaterial manufactured by the German biotech AMSilk. Is this the beginning of a new era for sustainable biomaterials? AMSilk, located near Munich, is the world’s first biotech supplying synthetic silk biopolymers for textiles, cosmetics and medical devices. The company’s 100% biodegradable and vegan […]

November 18, 2016 - 2 minutesmins - By Clara Rodríguez Fernández

antibiotic resistance biosensor freiburg

News and Trends 18 Nov 2016

Microfluidics and Biosensors to tackle Antibiotic Resistance

A little biosensor can analyze if there are antibiotics in your blood in 10 minutes. Developed by researchers from the University of Freiburg, the system could be used to develop a personalized course of antibiotics, but also to test food and water. The objective? Slow down the rise of multi-resistant bacteria. The World Antibiotic Awareness […]

November 18, 2016 - 3 minutesmins - By Denise Neves Gameiro

shutterstock 163202888

News and Trends 17 Nov 2016

Boehringer’s Biosimilar could take a Chunk out of the Cancer Market

Boehringer Ingelheim is getting ready to launch a biosimilar for Roche’s cancer blockbuster Avastin as soon as the patent expires. Can it overcome the fierce competition in a market expected to grow to 50% of the drug market by 2020? Boehringer Ingelheim just announced results from a Phase I trial showing that its biosimilar candidate […]

November 17, 2016 - 2 minutesmins - By Clara Rodríguez Fernández

shutterstock 489181960

News and Trends 17 Nov 2016

Germany steps up the fight against the Most Painful Disease

Grünenthal just acquired Thar Pharmaceuticals to pave the way towards treating complex regional pain syndrome (CRPS), considered one of the most painful conditions. Grünenthal, the company behind the thalidomide scandal in the 60s due to childbirth deformities, is now focusing on complex regional pain syndrome (CRPS), a rare orphan disease that causes prolonged and intense pain. In order […]

November 17, 2016 - 2 minutesmins - By Clara Rodríguez Fernández

ADVERTISEMENT

shutterstock 254171164

News and Trends 16 Nov 2016

New Private Placement to Boost the Profitable Therapeutic Antibody Market

MorphoSys has announced a private placement of shares to raise funds for its antibody therapy programs. With this push, the company is solidifying its position as a leader in the therapeutic antibody market, which is expected to reach €117B by 2021. MorphoSys, one of the few European billion euro biotechs, develops therapeutic antibodies for immuno-oncology, inflammatory […]

November 16, 2016 - 2 minutesmins - By Clara Rodríguez Fernández

teamwork collaboration Rawpixel.com fi

News and Trends 10 Nov 2016

Evotec chooses Oxford as Proving Ground for Academia-Industry Bridge

The German CRO has struck a deal with the University of Oxford to test a model framework for bringing academic research to the clinic faster. Evotec started out as a service provider in Hamburg, but thanks to former CEO Jörn Aldag, it has blossomed into a company that specializes in transforming newly discovered therapies into […]

November 10, 2016 - 3 minutesmins - By Evelyn Warner

shutterstock 245933788

News and Trends 9 Nov 2016

Up, up and away! CureVac’s money pile now Totals €325M

CureVac has raised an additional €27M ($29.5M) that will help the company keep on its track to be the first one to launch a mRNA therapy, a technology that can revolutionize how drugs are designed. CureVac is a German company in the billion-euro biotech club at the forefront of messenger RNA (mRNA) therapies, a technology that […]

November 9, 2016 - 3 minutesmins - By Clara Rodríguez Fernández

shutterstock 216981580

News and Trends 8 Nov 2016

These companies want to use Stem Cells to improve Drug Safety

Axiogenesis and Metrion Biosciences will use stem cells to improve preclinical neurotoxicity and cardiac safety testing, a feat that can significantly reduce the time and cost of drug discovery and clinical development. Axiogenesis is a Biotech from Cologne, Germany, that develops cell lines derived from induced pluripotent stem cells (iPSCs) for preclinical applications. The company […]

November 8, 2016 - 2 minutesmins - By Clara Rodríguez Fernández

30394585800 ba37b7c3ca o

News and Trends 3 Nov 2016

Which Teams are taking home Lego Trophies from iGEM this year?

The iGEM 2016 results are in! The world’s largest synthetic biology competition took place in Boston from the 24th to the 31st of October, and European teams took home the grand prizes in two of the three tiers, Postgraduate, Undergraduate and High School. The winners and their projects are listed below. Originally launched by Massachusetts Institute of Technology, […]

November 3, 2016 - 4 minutesmins - By Evelyn Warner

shutterstock 308293001

News and Trends 2 Nov 2016

Antibody Therapies are here to Revolutionize Dermatology

Leo Pharma is offering MorphoSys no less than €111.5M per antibody treatment with applications in dermatology, a very profitable field with big unmet needs. New cancer therapies might also arise from this exciting partnership! MorphoSys is a leader in the development of therapeutic antibodies with top-level partners like Novartis, Roche, Pfizer, Bayer, GSK, Galapagos […]

November 2, 2016 - 2 minutesmins - By Clara Rodríguez Fernández

ADVERTISEMENT